4 days ago
ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight, 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the ESCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ESCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report
Key Takeaways from the ESCLC Pipeline Report
In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
DelveInsight's ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment.
The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!" @ ESCLC Clinical Trials Assessment
ESCLC Emerging Drugs Profile
Serplulimab+Chemo: Shanghai Henlius Biotech
Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
RYZ101: RayzeBio, Inc.
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).
The ESCLC Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market.
From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! @ ESCLC Treatment Drugs
ESCLC Companies
Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
ESCLC Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Stay updated with the latest ESCLC Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives
Scope of the ESCLC Pipeline Report
Coverage- Global
ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ ESCLC Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Serplulimab+Chemo: Shanghai Henlius Biotech
Mid-Stage Products (Phase II)
Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Early Stage Products (Phase I)
RYZ101: RayzeBio, Inc.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
